Wcisło-Dziadecka Dominika, Zbiciak Martyna, Brzezińska-Wcisło Ligia, Mazurek Urszula
Department of Skin Structural Studies, Chair of Cosmetology, School of Pharmacy with the Division of Laboratory Medicine in Sosnowiec, Medical University of Silesia, Poland.
Chair and Department of Dermatology, School of Medicine in Katowice, Medical University of Silesia, Poland.
Postepy Hig Med Dosw (Online). 2016 Dec 8;70(0):1198-1205.
TNF‑α inhibitors - infliximab, etanercept and adalimumab - can be used in the treatment of psoriasis vulgaris and psoriatic arthritis, along with other inhibitors of proinflammatory cytokines, such as interleukin‑12 (IL‑12) and IL‑23. This paper presents the results of research on the use of biological drugs other than the tumor necrosis factor blockers (TNF‑α), namely inhibitors of IL‑12 and IL‑23 (ustekinumab), T‑cell inhibitors (alefacept and efalizumab), B‑cell inhibitors (rituximab), anti‑IL‑17 agents (secukinumab, ixekizumab, and brodalumab) and IL23p19 inhibitors (guselkumab and tildrakizumab). The paper presents an analysis of the mechanism of action, recommended doses and methods of therapy, taking into account the adverse events associated with the use of anti‑cytokine therapy. The use of biological drugs is discussed based on a review of the current literature.
肿瘤坏死因子-α抑制剂（英夫利昔单抗、依那西普和阿达木单抗）可与其他促炎细胞因子抑制剂（如白细胞介素-12（IL-12）和IL-23）一起用于治疗寻常型银屑病和银屑病关节炎。本文介绍了除肿瘤坏死因子阻滞剂（TNF-α）之外的生物药物的研究结果，即IL-12和IL-23抑制剂（优特克单抗）、T细胞抑制剂（阿法赛特和依法利珠单抗）、B细胞抑制剂（利妥昔单抗）、抗IL-17药物（司库奇尤单抗、伊塞克单抗和布罗达单抗）以及IL23p19抑制剂（古塞库单抗和替拉珠单抗）。本文在考虑抗细胞因子治疗相关不良事件的情况下，对作用机制、推荐剂量和治疗方法进行了分析。基于对当前文献的综述，讨论了生物药物的使用情况。
